See more : Shanshan Brand Management Co., Ltd. (1749.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Hillstream BioPharma, Inc. (HILS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hillstream BioPharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Link Real Estate Investment Trust (LKREF) Income Statement Analysis – Financial Results
- Agentix Corp. (AGTX) Income Statement Analysis – Financial Results
- LaSalle LOGIPORT REIT (3466.T) Income Statement Analysis – Financial Results
- Mercantile Ports & Logistics Limited (MPL.L) Income Statement Analysis – Financial Results
- Envipco Holding N.V. (ENVI.AS) Income Statement Analysis – Financial Results
Hillstream BioPharma, Inc. (HILS)
About Hillstream BioPharma, Inc.
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.56M | 2.28M | 1.84M | 847.27K | 368.73K |
| General & Administrative | 5.90M | 4.60M | 1.37M | 671.88K | 625.81K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.90M | 4.60M | 1.37M | 671.88K | 625.81K |
| Other Expenses | 0.00 | 0.00 | 1.83M | -362.49K | -26.46K |
| Operating Expenses | 9.46M | 6.88M | 3.21M | 1.52M | 994.54K |
| Cost & Expenses | 9.46M | 6.88M | 3.21M | 1.52M | 994.54K |
| Interest Income | 152.63K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | -16.51K | 1.59M | 831.28K | 246.53K | 75.07K |
| Depreciation & Amortization | 167.90K | 1.57B | 1.83M | -73.29K | 402.95K |
| EBITDA | -9.46M | -6.88M | -1.38M | -1.88M | -1.02M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.46M | -6.88M | -3.21M | -1.81M | -1.42M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 136.13K | -1.59M | 1.00M | -609.02K | -101.53K |
| Income Before Tax | -9.32M | -8.47M | -2.21M | -2.42M | -1.53M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 831.28K | -42.67K | -354.33K |
| Net Income | -9.32M | -8.47M | -3.04M | -2.37M | -1.17M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -7.14 | -0.75 | -0.30 | -0.21 | -0.10 |
| EPS Diluted | -7.14 | -0.75 | -0.30 | -0.21 | -0.10 |
| Weighted Avg Shares Out | 1.31M | 11.23M | 10.30M | 11.23M | 11.23M |
| Weighted Avg Shares Out (Dil) | 1.31M | 11.23M | 10.30M | 11.23M | 11.23M |
Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.
Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis
Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023
Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215
Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics
Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences
Why Is Hillstream BioPharma (HILS) Stock Down 57% Today?
10 Best-Performing Penny Stocks in the Health Care Sector
Hillstream BioPharma Provides Webcast for its R&D Day on February 14th, 2023 at 10:00am ET
Source: https://incomestatements.info
Category: Stock Reports